ScripAmgen’s updated Phase II data for MariTide in obesity may not have been the results the firm was looking for, but Amgen is trying to assure investors that based on learnings from an ongoing Phase II t
Pink SheetThe Biden Administration’s policies on price inflation rebates in Medicare and Medicaid unintentionally provided President Trump a tool to amplify the threat tariffs would pose to pharma. But Trump’s
Pink SheetPwC: Regulatory, Policy Uncertainty Constrain Dealmaking Life sciences deal volume and total valuation has been sluggish approaching the midpoint of 2025, even compared to the below-average numbers p
ScripWoodcock: Don’t Do The Wrong Study, Even If FDA Tells You To Janet Woodcock said she has told drug developers not to blindly follow agency advice, an unusual comment from a former US Food and Drug Adm